Surface Oncology Stock Cash Flow From Operations
| SURFDelisted Stock | USD 0.96 0.03 3.23% |
Surface Oncology fundamentals help investors to digest information that contributes to Surface Oncology's financial success or failures. It also enables traders to predict the movement of Surface Stock. The fundamental analysis module provides a way to measure Surface Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Surface Oncology stock.
Surface |
Surface Oncology Company Cash Flow From Operations Analysis
Surface Oncology's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Surface Oncology Cash Flow From Operations | (59.55 M) |
Most of Surface Oncology's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Surface Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
CompetitionIn accordance with the recently published financial statements, Surface Oncology has (59.55 Million) in Cash Flow From Operations. This is 111.29% lower than that of the Biotechnology sector and 195.25% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 106.13% higher than that of the company.
Surface Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Surface Oncology's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Surface Oncology could also be used in its relative valuation, which is a method of valuing Surface Oncology by comparing valuation metrics of similar companies.Surface Oncology is currently under evaluation in cash flow from operations category among its peers.
Surface Fundamentals
| Return On Equity | -1.06 | |||
| Return On Asset | -0.41 | |||
| Current Valuation | 18.31 M | |||
| Shares Outstanding | 60.82 M | |||
| Shares Owned By Insiders | 7.27 % | |||
| Shares Owned By Institutions | 46.03 % | |||
| Number Of Shares Shorted | 165.27 K | |||
| Price To Earning | 0.64 X | |||
| Price To Book | 0.47 X | |||
| Price To Sales | 1.60 X | |||
| Revenue | 30 M | |||
| Gross Profit | (37 M) | |||
| EBITDA | (61.87 M) | |||
| Net Income | (63.59 M) | |||
| Cash And Equivalents | 156.65 M | |||
| Cash Per Share | 2.70 X | |||
| Total Debt | 56.04 M | |||
| Debt To Equity | 0.45 % | |||
| Current Ratio | 8.19 X | |||
| Book Value Per Share | 0.81 X | |||
| Cash Flow From Operations | (59.55 M) | |||
| Short Ratio | 0.45 X | |||
| Earnings Per Share | (1.66) X | |||
| Target Price | 2.38 | |||
| Number Of Employees | 35 | |||
| Beta | 1.75 | |||
| Market Capitalization | 65.69 M | |||
| Total Asset | 159.91 M | |||
| Retained Earnings | (204.33 M) | |||
| Working Capital | 112.88 M | |||
| Current Asset | 22 K | |||
| Current Liabilities | 36 K | |||
| Z Score | -1.33 | |||
| Net Asset | 159.91 M |
About Surface Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Surface Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Surface Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Surface Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Surface Stock
If you are still planning to invest in Surface Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Surface Oncology's history and understand the potential risks before investing.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |